OBIO

Consensus

Buy4.00 / 56 ratings · Strong Buy 0 · Buy 6 · Hold 0 · Sell 0 · Strong Sell 0
Avg target $10.75+131.7%Median $10.00High $13.00Low $10.004 targets in the last 12 months

Price vs average target

Revenue and EPS estimates

ReportedConsensus estimates
Fiscal periodFY2021Dec '21FY2023Dec '23FY2024Dec '24FY2025Dec '25FY2026Dec '26FY2027Dec '27FY2028Dec '28FY2029Dec '29FY2030Dec '30
Revenue (M)−1.22.82.63.50.50.613.950.7109.5
Growth YoY–−35.9%−4.4%+31.5%−86.9%+27.2%+2303.5%+265.4%+116.1%
High estimate–––3.60.51.336.8126.9274.3
Low estimate–––3.30.40.35.422.548.7
Analysts–––566522
EPS, adjusted−0.19−1.50−1.61−1.74−1.52−1.51−0.95−0.400.29
Growth YoY–n/mn/mn/mn/mn/mn/mn/mn/m
High estimate–––−1.68−1.45−1.37−0.55−0.110.86
Low estimate–––−1.78−1.64−1.69−1.28−1.180.08
Analysts–––655411

Consensus mean of analyst estimates. EPS is adjusted (street) EPS, the basis analysts forecast; annual actuals are the sum of the four reported quarters. Growth compares with the same period a year earlier; n/m where the prior period was a loss.

Brokers

6 firms active in the last 12 months
FirmAnalystRatingPrev ratingTargetPrev targetChgUpsideDate
H.C. WainwrightYi ChenBuy · May 2026Buy$10.00––+116%Oct 5
B. Riley Securities–BuyBuy––––Sep 15
BTIGMarie ThibaultBuyNeutral$10.00$12.00−17%+116%Sep 10
Piper SandlerMatt O'BrienOverweightOverweight$10.00––+116%Aug 11
BarclaysMatt MiksicOverweightOverweight$13.00$12.00+8%+180%May 13
Chardan Capital–BuyBuy––––Mar 12

Latest analyst action Page refreshed hourly; analyst feeds refreshed dailyAbout this data

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.